CCC are meeting with ASCO today, to launch the Quality Cancer Medicine Forum. The Forum will GO LIVE on 8th June……….. Register now at https://cancercarecommission.within3.com to get your invite to participate.
It’s time to register for this hugely anticipated, innovative Crowdsourcing event. Go to https://cancercarecommission.within3.com to register and to find out more information about the event, go to http://www.cancercarecommission.com and click on THE RED BUTTON on the right side of page, or the ‘Quality Cancer Medicine Forum’ page at the top left side of website.
CCC are launching the above event in association with ASCO in June 2022. Watch this space for further information on this innovative crowdsourcing ‘Hackathon’ event.
World Cancer Day: a leading international awareness day
World Cancer Day held every 4 February is the global uniting initiative led by the Union for International Cancer Control(UICC). By raising worldwide awareness, improving educationand catalysing personal, collective and government action, we are all working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all – no matter who you are or where you live.
Created in 2000, World Cancer Day has grown into a positive movement for everyone, everywhere to unite under one voice to face one of our greatest challenges in history.
Following an enlightening and illuminating debate in the CCC Expert Panel forum, including delegates from ASCO, NCCN, WHO and emeritus Health Ministers, clear objectives have been identified for the CCC Crowdsourcing event, namely to Gather and share:
- Real world evidence and insights into substandard-quality cancer medicines
- Identify solutions and policy changes to protect patients and improve healthcare system efficiencies
The expectation is that healthcare professionals and policymakers will not only better understand the implications of substandard delivery of oncology cancer care, but be provided with real-world recommendations on how to mitigate them and even measure the impact.
Watch for updates on THE Crowdsourcing event of 2022 ……
CCC’s long standing supporter AMGEN, brings breakthrough drug to NHS for Lung Cancer patients
NHS lung cancer patients will be the first in Europe to be offered a revolutionary new drug which stops tumours growing by targeting the so-called “death star” mutation.
The cutting-edge therapy Sotorasib will be fast-tracked to NHS patients after being proven in clinical trials to stop lung cancer growing for seven months.
The drug’s adoption by NHS follows a 40 year search for a treatment for the mutation on the KRAS gene, present in a quarter of all tumours, which has been dubbed the “Death Star” because of its spherical appearance and impenetrable nature.
Around 600 NHS lung cancer patients a year will be given the drug initially in England, starting in the next few weeks thanks to an early-access deal.
Sotorasib, taken as a tablet, binds with the KRAS G12C mutation and makes it inactive, stopping cell division and cancer growth.
It is the first treatment of its kind and could represent a major breakthrough in treatments for some of the world’s other deadliest cancers including pancreatic and colorectal cancers.
NHS England, NICE and manufacturer Amgen have reached an agreement to enable early access to sotorasib for eligible lung cancer patients in England on a budget-neutral basis to the NHS while NICE completes its ongoing appraisal.
Dr Tony Patrikios, Executive Medical Director, Amgen UK and Ireland, said: “Amgen’s first-in-class medicine, sotorasib, is the culmination of a 40-year quest to target this cancer gene mutation which is known to drive the growth of certain cancers. As an oral targeted therapy, this represents a new option for specific non-small cell lung cancer patients, and we are delighted to partner with NHS England to make this treatment available to those patients who may benefit from it, as quickly as possible.”
Dr.Nidhin is a consultant radiation oncologist at Kerala,the southern part of India. He trained at 2 of the oldest medical colleges of the country-govt medical college, Trivandrum and Madras medical college Chennai , he went on to have NHS training at the Royal Marsden Hospital,UK. He was Recipient of the prestigious Neil Joseph Fellowship and resident fellowship from YROC and presenter at various international conferences across the globe. He has held various high profile positions throughout the continent. He retains his Global leadership panel membership for fight cancer Global USA , Visiting faculty member at university of Kerala & was the past General secretary of Young radiation oncologists forum.
He has been a key associate and champion of CCC since 2016 in the capacity of a consultant, for establishing accreditation and quality improvement of cancer centres across India and China. CCC are delighted to continue our collaboration and friendship with Dr Nidhin.
Earlier today (01/07/21) CCC facilitated a Global Expert Virtual Panel and asked two questions: 1. Based on your experience, where can the most significant breakdown be, in the delivery of cancer patients who need them? and 2.Who are the key audiences that should be aware of these potential issues; How do you think we can reach them and what would compel them to take action?
Following a 2hr+ discussion, with each panelist providing great insight and innovative forward planning, CCC will capture the collective reflections and take them forward in a meaningful way. Watch this space for the next, exciting, ground breaking steps !
Quality of Medicine Expert Panel 1 July 2021
Cancer Care Commission will bring together a Global Expert panel to debate the issues and potential solutions in the delivery of high quality cancer medicines. The outcomes from the meeting will inform and shape a Crowdsourcing Campaign later in the year……watch this space for updates.
Quality of Medicine Initiative Objective: Identify real-world insights and solutions for healthcare professionals in delivery of high-quality cancer medicines via an online Crowdsourcing Campaign*